Why the study?
As life expectancy in chronic myeloid leukemia approaches that of the age-matched population, quality of life issues have become increasingly important.
Do second-generation tyrosine kinase inhibitors compared to first-generation inhibitors affect quality of life in patients with chronic myeloid leukemia?
Cross-Sectional (n=139)
Do second-generation tyrosine kinase inhibitors compared to first-generation inhibitors affect quality of life in patients with chronic myeloid leukemia?
p-value: p=0.02
In patients with CML, those treated with imatinib reported better quality of life compared to those on second-generation TKIs, though this finding is strongly associated with age differences between the treatment groups.
The life expectancy of patients with chronic myeloid leukemia (CML) approaches that of the age-matched population and quality of life (QOL) issues are becoming increasingly important. To describe patients’ characteristics and assess QOL, we delivered a 30-item core questionnaire, a 24-item CML-specific questionnaire, both from the European Organization for Research and Treatment of Cancer (EORTC), and additional health-related items to 350 patients. Among 193 patients who completed the questionnaires, 139 received either imatinib (n = 70, 33%), dasatinib (n = 45, 23%) or nilotinib (n = 24, 12%). Patients’ median age was 58 (range: 23 to 89) years and 86 (63%) were males. Stratifying patients by treatment, we recognized two distinct populations. In comparison to patients on dasatinib and nilotinib, patients on imatinib were two decades older, had a longer duration of disease and current treatment, experienced fewer limitations on daily activities (p = 0.02), less fatigue (p = 0.001), lower degree of impaired body image (p = 0.022) and less painful episodes (p = 0.014). Similarly, they had better emotional functioning, were less worried, stressed, depressed or nervous (p = 0.01) and were more satisfied with their treatment (p = 0.018). Not only does age associate with current treatments, but it also predicts how patients perceive QOL. Young patients express impaired QOL compared with elderly patients.
No takes yet. Share an insight, caveat, or question.
Abulafia et al. (2020) conducted a cross-sectional in Chronic myeloid leukemia (n=139). Imatinib vs. Dasatinib or nilotinib was evaluated on Quality of life (limitations on daily activities) (p=0.02).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: